Other CAR candidates such as prostate‐specific membrane antigen (PSMA) targeting prostate cancer; mucin1 (MUC1) targeting non‐small cell lung cancer; MSLN, anthrax toxin receptor 1 (anthrax toxin receptor 1, ANTXR1) and MUC3A targeting gastric adenocarcinoma; epidermal growth factor receptor variant III (EGFRv III) and IL13R2 targeting glioblastoma (GBM) have shown promise in preclinical studies. Here, FOLH1 is linked to glioblastoma.